Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan's Fulphila Sets Up The US Market For The Next Biosimilar Showdown

Executive Summary

Mylan has priced its biosimilar version of pegfilgrastim at a 33% discount to Amgen's WAC for Neulasta, steeper than the 15% discount Pfizer initially offered for Inflectra. The commercial outcome for Fulphila could set the tone for future US biosimilars, which have yet to take off.

Advertisement

Related Content

Mylan’s Fulphila: First Neulasta Biosimilar’s Road To US Market Slowed Only By Product Quality, GMP Deficiencies
Keeping Track: FDA Starts November With A Bang
Mylan Head Of Biologics Chrys Kokino On Fulphila Launch And US Biosimilars
Enthusiasm For US Biosimilars Wanes For Some, But Not Others
Generic Drug Sector Struggles Even As The Need For Cheaper Drugs Grows
Mylan Is First To Clear US Neulasta Biosimilar Hurdle; At-Risk Launch May Not Be Risky
Mylan Poised To Launch Its First US Biosimilar, With A Stacked Pipeline Behind It
FDA's Gottlieb: 'Pricing And Reimbursement Mischief' Holding Back Biosimilar Market
Pfizer Sets The Stage For A Biosimilar Showdown Over Exclusive Contracts
Exclusive Remicade Contracts Are Slowing Biosimilar Uptake

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123406

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel